3-hydroxypregn-4-en-20-one has been researched along with flunitrazepam in 1 studies
| Studies (3-hydroxypregn-4-en-20-one) | Trials (3-hydroxypregn-4-en-20-one) | Recent Studies (post-2010) (3-hydroxypregn-4-en-20-one) | Studies (flunitrazepam) | Trials (flunitrazepam) | Recent Studies (post-2010) (flunitrazepam) |
|---|---|---|---|---|---|
| 29 | 0 | 2 | 2,697 | 298 | 130 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolger, MB; Gee, KW; Hawkinson, JE; Kimbrough, CL; Lan, NC; McCauley, LD | 1 |
1 other study(ies) available for 3-hydroxypregn-4-en-20-one and flunitrazepam
| Article | Year |
|---|---|
The neuroactive steroid 3 alpha-hydroxy-5 beta-pregnan-20-one is a two-component modulator of ligand binding to the GABAA receptor.
Topics: 20-alpha-Dihydroprogesterone; Animals; Brain Chemistry; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cattle; Cerebellum; Convulsants; Flunitrazepam; Hippocampus; In Vitro Techniques; Ligands; Male; Membranes; Receptors, GABA-A; Thalamus | 1994 |